Platinum and etoposide in chemotherapy refractory metastatic breast cancer. A phase II trial of the Italian oncology group for clinical research (G.O.I.R.C.)

European Journal of Cancer and Clinical Oncology

Volumn 22, Issue 7, 1986, Pages 761-764

  Cocconi, Giorgio ^a   Tonato, Maurizio ^b   di Costanzo, Francesco ^c   Bisagni, Giancarlo ^a   Belsanti, Virginio ^c   Buzzi, Franco ^c   Ceci, Guido ^a  

^a MAGGIORE HOSPITAL   (Italy)

^b Medical Oncology Division Ospedale Regionale of Perugia ^*  (Italy)

^c S MARIA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; ETOPOSIDE;

ADVERSE DRUG REACTION; BLOOD AND HEMOPOIETIC SYSTEM; BONE MARROW DEPRESSION; BREAST; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CHEMOTHERAPY; CLINICAL ARTICLE; DRUG EFFICACY; DRUG THERAPY; GASTROINTESTINAL TOXICITY; HUMAN; INTOXICATION; INTRAVENOUS DRUG ADMINISTRATION; METASTASIS; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THERAPY; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CISPLATIN; DRUG EVALUATION; ETOPOSIDE; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM TRANSPLANTATION;

EID: 0022528943     PISSN: 02775379     EISSN: None     Source Type: Journal    
DOI: 10.1016/0277-5379(86)90360-3     Document Type: Article

References (26)

1. A phase II trial of cis-dichlorodiammineplatinum II in breast and ovarian carcinomas
2. Preliminary clinical experience with cis-diamminedichloroplatinum (II) (NSC1119875, CACP)
3. High dose cis-diamminedichloroplatinum therapy in patients with advanced breast cancer: pharmacokinetics, toxicity and therapeutic efficacy
4. Cis-diamminedichloroplatinum (CDDP) in advanced breast and colorectal carcinomas
5. Phase II study of cis-dichlorodiammineplatinum (II) in advanced breast cancer
6. Cis-platin in the treatment of metastatic breast carcinoma
7. Phase II clinical trial of cis-dichlorodiammine platinum (cis-DDP) for antitumorigenic activity in previously untreated patients with metastatic breast cancer
8. Phase II evaluation of VP16–213 in patients with advanced breast cancer: a Southwest Oncology Group Study
9. Phase II study of VP16–213 (etoposide) in refractory metastatic breast carcinoma
10. Studies of cross-resistance, synergistic combinations and blocking of activity of platinum derivatives
11. Podophyllotoxin derivative VP16–213
12. Therapeutic synergism in murine tumors for combinations of cisdiamminedichloroplatinum with VP16–213 or BCNU
13. Cis-dichlorodiammineplatinum (II): combination chemotherapy and cross-resistance studies with tumours of mice
14. Kinetics of VP-16 epipodophyllotoxin in children with cancer
15. Assessment of response to therapy in advanced breast cancer
16. Etoposide and cis-platinum in non-small cell bronchogenic carcinoma
17. VP16 plasma levels after i.v. and two methods of oral administration to choriocarcinoma patients
18. An effective low-dose mitomycin regimen for hormonal and chemotherapy-refractory patients with metastatic breast cancer
19. Mitomycin C in metastatic breast cancer resistant to hormone therapy and conventional chemotherapy
20. Continuous five-day infusion of vinblastine for refractory metastatic breast cancer
21. Phase II study of vinblastine infusion in the treatment of refractory advanced breast cancer
22. Failure of 5-day vinblastine infusion in the treatment of patients with advanced refractory breast cancer
23. Vindesine
24. Mitomycin C and vinblastine chemotherapy for advanced breast cancer
25. Mitomycin C (M) and vinblastine (V) in the treatment of advanced breast cancer
26. Cisplatin plus vindesine in multitreated advanced breast cancer